Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster

Annexon, Inc.

Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).
ANX005 patients walked 31 days earlier and came off ventilation 28 days earlier vs placebo.
At Week 26, 21.5% of ANX005 patients fully recovered (GBS-DS=0) vs 8.6% on placebo (OR 4.14, p=0.0092).
Subgroup with North American/European baseline characteristics showed 3x greater likelihood of better health state at Week 8.
Single infusion generally well-tolerated; safety profile similar to placebo, no increased infections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.